AIHTA - Publications - Search - Items where Subject is "WI 700-770 Liver. Billary tract"
Number of items at this level: 22.

Falkner, E. and Wild, C. (2008): Clinical application of Tissue Engineering: An overview of International and Austrian Areas of Research with a critical analysis of selected applications . LBI-HTA Projektbericht 013.

Fischer, S. and Zechmeister-Koss, I (2012): Day Surgery. HTA- Projektbericht 64.

Grössmann, N. (2021): Pemigatinib (Pemazyre®) for the treatment of adults with locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or rearrangement. Update May 2021. Oncology Fact Sheet Nr. 40.

Grössmann, N. (2021): Atezolizumab (Tecentriq®) plus bevacizumab for the treatment of advanced or unresectable hepatocellular carcinoma (HCC). Update February 2021. Oncology Fact Sheet Nr. 20.

Gugerbauer, J. and Warmuth, M. (2011): Radiofrequency ablation for hepatocellular carcinoma and colorectal liver metastases. Decision Support Document 049.

Haute Autorité de Santé (HAS), EUnetHTA and Autoridade Nacional do Medicamento e Productos de Saude (INFARMED), EUnetHTA (2017): Regorafenib indicated as monotherapy for the treatment of adult patients with hepatocellular carcinoma (HCC) who have previously been treated with sorafenib. EUnetHTA report. DSD: Horizon Scanning in Oncology 73.

Kisser, A. (2016): Hepatitis C virus screening in hospitals. Decision Support Document 102.

Nachtnebel, A. and Sotti, G. and Vitale, A. and Perrini, MR. (2011): Selective internal radiotherapy using yttrium-90 microspheres for primary and secondary liver malignancies. German version. Decision Support Document 47.

Nachtnebel, A. and Sotti, G. and Vitale, A. and Perrini, MR. (2011): Selective internal radiotherapy using yttrium-90 microspheres for primary and secondary liver malignancies. English version. Decision Support Document 47.

Rothschedl, E. and Wolf, S. (2022): Pembrolizumab (Keytruda®) as monotherapy for the treatment of microsatellite instability-high (MSI‑H) or mismatch repair deficient (dMMR) tumours in adults with unresectable or metastatic colorectal cancer, advanced or recurrent endometrial carcinoma and unresectable or metastatic gastric, small intestine, or biliary cancer. Oncology Fact Sheet Nr. 90.

Rothschedl, E. and Nachtnebel, A. (2015): Defibrotide for the treatment and prophylaxis of hepatic veno-occlusive disease. Decision Support Document 84.

Schmidt , L. and Lohr, P. and Prenner, A. and Poerio, E. and Ceresola, E. and Andretta, M. and Cavazzana, A. (2019): Robot-assisted surgery in thoracic and visceral indications. HTA-Projektbericht 108.

Wild, C. (2004): [Prevention and therapy of Hepatitis C]. HTA-Newsletter 29: pp. 3-4.

Wild, C. (2004): [ERCP vs. MRCP: Diagnostics of biliary tract diseases]. HTA-Newsletter 27: pp. 2-3.

Wild, C. (2004): [Photodynamic therapy/PDT]. HTA-Newsletter 27: p. 4.

Wild, C. (2004): [Radiofrequency ablation: Therapy of liver tumours] . HTA-Newsletter 26: p. 4.

Wild, C. (2003): [MARS® liver support]. HTA-Newsletter 20: p. 2.

Wild, C. (2003): [Pegylated interferon alpha for chronic hepatitis C]. HTA-Newsletter 17: pp. 3-4.

Wild, C. (2002): [Living donor transplantation]. HTA-Newsletter 11: pp. 3-4.

Wild, C. (2002): [Laser-induced thermotherapy (LITT) in the treatment of malignant tumours]. HTA-Newsletter 06: p. 2.

Wild, C. and Patera, N. (2014): Stereotactic Radiofrequency ablation/ SRFA for hepatocellular carcinoma and liver metastases. Decision Support Document 76.

Zapata Cachafeiro, M. and Varela Lema, L. and Faraldo Vallés, M.J. and Fuchs, E. (2019): Irreversible electroporation for the treatment of liver and pancreatic cancer. HTA-Projektbericht 119.

This list was generated on Fri May 20 02:00:25 2022 CEST.